Press Space to continue
Personalized mRNA cancer vaccine succeeds in Phase 3 trial
Press Space to continue
SITUATION DETECTED: A personalized Moderna-Merck mRNA cancer vaccine has succeeded in a Phase 3 melanoma trial, the first late-stage win for an individualized mRNA cancer therapy. The companies announced the result today, and Moderna’s stock surged about 90% on the news.
open on x · 1 viewViews and clicks count once per visitor per day. Clicks are opens of this post on X.